Literature DB >> 9458560

The case for a heroin substitution treatment trial in Canada.

B Fischer1, J Rehm.   

Abstract

Illicit opiate use in Canada causes considerable harm and social cost. Methadone substitution treatment, which has been proven effective in reducing the negative effects associated with opiate use, has been used in Canada, but so far only on a small scale. Recent research suggests that, while expanding the availability of methadone substitution is certainly in the public health interest, it would not be sufficient in itself to reduce to a minimum the harms from illicit opiate use. On the basis of the epidemiology of opiate use and of related harms, and building on the experience of intervention efforts currently underway elsewhere, this paper argues for the establishment of a heroin substitution trial in Canada. Such a trial should have the goal of investigating the potential of heroin substitution to significantly reduce the health and social costs to Canadians from illicit opiate use.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9458560

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  10 in total

1.  Chasing the dragon--neurological toxicity associated with inhalation of heroin vapour: case report.

Authors:  M D Hill; P W Cooper; J R Perry
Journal:  CMAJ       Date:  2000-01-25       Impact factor: 8.262

2.  Social costs of untreated opioid dependence.

Authors:  R Wall; J Rehm; B Fischer; B Brands; L Gliksman; J Stewart; W Medved; J Blake
Journal:  J Urban Health       Date:  2000-12       Impact factor: 3.671

3.  Injection drug use and preventive measures: a comparison of Canadian and western European jurisdictions over time.

Authors:  B Fischer; J Rehm; T Blitz-Miller
Journal:  CMAJ       Date:  2000-06-13       Impact factor: 8.262

4.  Illicit opioid use in Canada: comparing social, health, and drug use characteristics of untreated users in five cities (OPICAN study).

Authors:  Benedikt Fischer; Jürgen Rehm; Suzanne Brissette; Serge Brochu; Julie Bruneau; Nady El-Guebaly; Lina Noël; Mark Tyndall; Cameron Wild; Phil Mun; Dolly Baliunas
Journal:  J Urban Health       Date:  2005-05-04       Impact factor: 3.671

5.  Buprenorphine: a potential new treatment option for opioid dependence.

Authors:  Anita Srivastava; Meldon Kahan
Journal:  CMAJ       Date:  2006-06-20       Impact factor: 8.262

6.  Why we object to NAOMI. Heroin maintenance in Canada.

Authors:  Meldon Kahan; Anita Srivastava; Kay Shen
Journal:  Can Fam Physician       Date:  2006-06       Impact factor: 3.275

7.  Patterns of methadone maintenance treatment provision in Ontario: Policy success or pendulum excess?

Authors:  Paul Kurdyak; Binu Jacob; Juveria Zaheer; Benedikt Fischer
Journal:  Can Fam Physician       Date:  2018-02       Impact factor: 3.275

8.  Determinants of overdose incidents among illicit opioid users in 5 Canadian cities.

Authors:  Benedikt Fischer; Suzanne Brissette; Serge Brochu; Julie Bruneau; Nady el-Guebaly; Lina Noël; Jürgen Rehm; Mark Tyndall; Cameron Wild; Phil Mun; Emma Haydon; Dolly Baliunas
Journal:  CMAJ       Date:  2004-08-03       Impact factor: 8.262

9.  Too much or never enough: a response to Treatment of opioid disorders in Canada: looking at the 'other epidemic'.

Authors:  Joseph K Eibl; Kristen A Morin-Taus; David C Marsh
Journal:  Subst Abuse Treat Prev Policy       Date:  2016-09-20

10.  It's time for Canadian community early warning systems for illicit drug overdoses.

Authors:  Sarah J Fielden; David C Marsh
Journal:  Harm Reduct J       Date:  2007-03-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.